1. Schiefer, M, Hendriks, LEL, Dinh, T, et al. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Eur J Cancer 2018; 91: 92–98. PMID: 29413968.
Google Scholar | Crossref | Medline2. Kunimasa, K, Oka, T, Hara, S, et al. Osimertinib is associated with reversible and doseindependent cancer therapy-related cardiac dysfunction. Lung Cancer 2021; 153: 186–192. Epub 2020 Nov 16. PMID: 33277055.
Google Scholar | Crossref | Medline3. Naranjo, CA, Busto, U, Sellers, EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
Google Scholar | Crossref | Medline | ISI4. Kramer, MS, Hutchinson, TA. The Yale algorithm. Special workshop—clinical. Drug Inf J 1984; 18: 283–291.
Google Scholar | SAGE Journals5. Mashford, ML . The Australian method of drug-event assessment. Special workshop-regulatory. Drug Inf J 1984; 18: 271–273.
Google Scholar | SAGE Journals6. Michel, DJ, Knodel, LC. Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm 1986; 43: 1709–1714.
Google Scholar | Medline7. Ikebe, S, Amiya, R, Minami, S, et al. Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma. Int Cancer Conf J 2020; 10: 68–71. PMID: 33489705; PMCID: PMC7797397.
Google Scholar | Crossref | Medline8. Kunimasa, K, Kamada, R, Oka, T, et al. Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC Cardio Oncol 2020; 2: 1–10.
Google Scholar | Crossref | Medline9. Bian, S, Tang, X, Lei, W. A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin. BMC Pulmonary Med 2020; 20: 1–5.
Google Scholar | Crossref | Medline10. Kondo, M, Kisanuki, M, Kokawa, Y, et al. Case report: QT prolongation and abortive sudden death observed in an 85-year-old female patient with advanced lung cancer treated with tyrosine kinase inhibitor Osimertinib. Front Cardiovasc Med 2021; 8: 655808.
Google Scholar | Crossref | Medline11. Jänne, PA, Yang, JC, Kim, DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689–1699. PMID: 25923549.
Google Scholar | Crossref | Medline | ISI12. Goss, G, Tsai, C-M, Shepherd, FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17: 1643–1652.
Google Scholar | Crossref | Medline | ISI13. Soria, JC, Ohe, Y, Vansteenkiste, J, et al.. Osimertinib in untreated EGFR mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–125. Epub 2017 Nov 18. PMID: 29151359.
Google Scholar | Crossref | Medline | ISI14. Sadasivan, C, Zhabyeyev, P, Labib, D, et al. Cardiovascular toxicity of PI3Ka inhibitors. Clin Sci 2020; 134: 2595–2622.
Google Scholar | Crossref15. Mok, TS, Wu, YL, Ahn, MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790Mpositive lung cancer. N Engl J Med 2017; 376: 629–640.
Google Scholar | Crossref | Medline | ISI16. Mezquita, L, Varga, A, Planchard, D. Safety of Osimertinib in EGFR mutated non-small cell lung cancer. Expert Opin Drug Saf 2018; 17: 1239–1248.
Google Scholar | Crossref | Medline17. Zaborowska-Szmit, M, Krzakowski, M, Kowalski, DM, et al. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med 2020; 9: 1268. PMID: 32349387; PMCID: PMC7287714.
Google Scholar | Crossref18. Ewer, MS, Tekumalla, SH, Walding, A, et al. Cardiac safety of Osimertinib: a review of data. J Clin Oncol 2021; 39: 328–337. Epub 2020 Dec 23. PMID: 33356419; PMCID: PMC8078322.
Google Scholar | Crossref | Medline19. Curigliano, G, Lenihan, D, Fradley, M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31: 171–190.
Google Scholar | Crossref | Medline